Instytut Biochemii I Biofizyki Polskiej Akademii Nauk

Miedzynarodowy Instytut Biologii Molekularnej I Komorkowej

Oncoarendi Therapeutics Sp. Z O.o.

Miedzynarodowy Instytut Biologii Molekularnej I Komorkowej W Warszawie

Marcin Nowotny

Adam A Golebiowski

Jacek P Olczak

Janusz Marek Bujnicki

Agata Agnieszka Sulej

Krzysztof Jerzy Skowronek

Andrzej Dziembowski

Rafal Tomecki

Karolina Drazkowska

Roman Szczesny

Krystian Stodus

Weronika Jonko

Adam Golebiowski

Jacek Olczak

The present invention relates to a method for selection or screening of hDIS3 PIN domain inhibitors, yeast strain and cell line used in such methods It also relates to new therapeutic agents selected hDIS3 PIN domain inhibitors and uses thereof in the treatment of cancers having mutations inhDIS3 RNB domain, especially multiple myeloma. The invention also relates to composition comprising new therapeutic agent hDIS3 PIN domain inhibitor and method for inducing synthetic lethality in a cancer cell.

Method for selection of hDIS3 PIN domain inhibitors and use of hDIS3 PIN domain inhibitors for cancer treatment

The subject of the invention is the ribonuclease which cleaves RNA strand in DNA-RNA hybrids, wherein ribonuclease comprises fusion protein comprising catalytic domain of RNase HI (RNase HI) or derivative thereof with a zinc finger DNA-RNA hybrid binding domain, and wherein the zinc finger binding domain has the ability to bind to specific sequences in the DNA-RNA hybrid. The invention also relates to new methods for determination of the sequence preference of DNA-RNA hybrid binding protein(s) or its domain(s) and allows determining the sequence recognized by sequence specific binding protein in the DNA-RNA hybrid.

Sequence-specific engineered ribonuclease H and the method for determining the sequence preference of DNA-RNA hybrid binding proteins

Growing community of inventors

Warsaw, Poland

Marcin Nowotny